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Abstract: Although most viral infections cause minor, if
any, symptoms, a certain number result in serious illness.
Viral disease symptoms result both from direct viral
replication within host cells and from indirect immuno-
pathological consequences. Dendritic cells (DCs) are key
determinants of viral disease outcome; they activate
immune responses during viral infection and direct T
cells toward distinct T helper type responses. Certain
viruses are able to skew cytokine secretion by DCs
inducing and/or downregulating the immune system
with the aim of facilitating and prolonging release of
progeny. Thus, the interaction of DCs with viruses most
often results in the absence of disease or complete
recovery when natural functions of DCs prevail, but may
lead to chronic illness or death when these functions are
outmanoeuvred by viruses in the exploitation of DCs.
Introduction
Viruses are major targets of the immune system. A variety of viral
pathogen-associated molecular patterns (PAMPs), such as the high
repetition of capsomers and/or peplomers on virion surface, the
production of unique RNA replication intermediates and genome
modifications, and others, are recognized as markers of viral
invasion by responsive molecules on immune effector cells (see
Figure 1). The integration of stimuli delivered by different viral
PAMPs leads to inflammation and immune activation which, in
turn, are key components of both pathogenesis and recovery from
viral infection. Dendritic cells (DCs) possess properties and abilities
enabling them to act as unique immune ‘‘live adjuvants’’ [1]. Like
no other antigen-presenting cell, they can perform multiple
immunogenic tasks, including i) priming of naı ¨ve T cells by the
expression of special costimulatory surface molecules; ii) cross-
presentation, that is, presentation of exogenous antigens in the
context of MHC class I molecules to CD8
+ T lymphocytes, in
addition to presentation of MHC class II-restricted peptides; and iii)
polarizing naı ¨ve T cells to various Th phenotypes. DC activity is
normally triggered by pathogens via a variety of receptor molecules
and includes the release of distinct interleukins (ILs) directed at
regulating T cell differentiation [2]. Indeed, the secretion of soluble
mediators seems to be responsible for Th phenotype differentiation
and is now considered ‘‘signal 3’’, after MHC-peptide recognition
(signal 1) and contact of costimulatory molecules (signal 2) [3]. The
secretion of IL-12, IL-18, tumor necrosis factor (TNF)-a,a n d
interferon(IFN)-a is associated with skewing naı ¨veT cells towards a
Th1 phenotype, whileTh2cells areproduced inthe absence of such
cytokines and in the presence of IL-10. In addition, transforming
growth factor (TGF)-b induces Foxp3 and promotes the generation
of CD25
+ CD4
+ T regulatory (Treg) cells, while IL-6 inhibits the
generation of Treg cells and induces the production of T helper 17
(Th17) cells, suggesting another reciprocal developmental pathway
for CD4
+ T cells [4]. In turn, Treg cells hinder DCs and/or normal
CD4
+ T cells in their activities, while Th17 cells are involved in
inflammatory and autoimmune reactions [5].
Due to different origin, distribution in tissues, and expression of
surface receptors, DCs have been divided into conventional (cDCs)
and plasmacytoid DCs (pDCs); they differ in immunomodulatory
functions and preferentially react to distinct microbial stimuli.
cDCs, also known as myeloid DCs, include migratory cells and
lymphoid-resident cells that cooperate and are essential to one
another to turn on a T cell response. cDCs are mostly devoted to
taking up antigen in their steady state and presenting it to T cells
in their activated or mature state. Recent evidence shows that
early antigen presentation by lymphoid-resident DCs initiates
activation and trapping of antigen-specific T lymphocytes in the
draining lymph node, while migratory DCs interact with such T
cells to induce clonal expansion [6]. In addition, cDCs can
recognize cytoplasmic viral RNA by endosomal Toll-like receptor
(TLR)-3, binding double-stranded RNA [7], and cytoplasmic
receptors such as retinoic-acid-inducible protein I (RIG-I), a
helicase that has been shown to bind 59 triphosphorylated ends in
single-stranded RNA present only in certain viral genomes, and
melanoma-differentiation-associated gene 5 (MDA5), and start
type I IFN production [8–10]. To study human DCs, cDCs
generated in vitro by differentiation of peripheral blood monocytes
in the presence of specific cytokines have been extensively used in
many studies. However, the results obtained with in vitro-
generated cDCs must be interpreted with caution since recent
evidence indicates that in vitro conditions may select at least one
specific subset [11]. In this respect, there will probably be
abundant new insight into the field brought by studies on
humanized mice that exhibit long-term systemic human T cell
reconstitution in vivo, allowing for the manifestation of the
differential response by human DCs to different pathogens [12].
DCsofthe second subset,pDCs,seemtobedesignedtobepart of
the first line of defense against viral and intracellular parasite
replication: they express endosomal nucleic-acid sensing TLR-7,
TLR-8, and TLR-9, that, once triggered, are mostly responsible for
the release of type I IFN by these cells [13]. Very recently, however,
pDCs were shown to also be capable of cross-presenting viral
antigens and to behave as ‘‘ready-made stores of MHC class I’’ that
can be charged in endosomes independently of proteasome activity;
pDCs are therefore also able to quickly prime CD8
+ cytotoxic
activity upon interaction with virus [14]. pDCs can be normally
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numbers from human peripheral blood where they are recognized
as CD123
+, CD11c
2 cells. As will be discussed further on, most of
the data on their role in vivo indicate that a reduction in pDC
response is inversely correlated with severity in viral diseases.
To present antigen to T cells, DCs must move from their
locations to lymph nodes. The ability to migrate to lymph nodes,
as well as to express costimulatory molecules responsible for
activating naı ¨ve T cells in germinal centers, is acquired through
maturation. Such a state, also called activation, is achieved after
virus uptake by triggering one of two kinds of receptors: i)
receptors recognizing PAMPs, including TLRs on the cell surface
and endosomes, as well as cytosolic RIG-1 and MDA5, reacting to
intracellular parasite motifs [15,16]; and ii) receptors recognizing
cytokines, chemokines, and cell surface proteins produced by the
host, e.g., the TNF superfamily. Maturation also leads to the
expression of different surface molecules; one of the best markers
for human DC maturation is CD83, which is highly expressed by
mature DCs both in a membrane-bound and in a soluble secreted
form. At least under some circumstances, soluble CD83 seems to
have an immunosuppressive effect, as demonstrated by its ability
to prevent autoimmune encephalomyelitis in mice [17].
When susceptible (permissive) target cells are not present at the
site of viral entry in hosts, cDCs are amongst the first cells
encountered bymostviruses, simply duetotheir availabilityatevery
possible entry site of the body. This has been formally shown for
HIV-1 in an ex vivo organ culture system reproducing the human
vagina; in this setting, CD4
+ T cells present in vaginal epithelium
and Langerhans DCs are the first cells invaded by the virus [18].
Viruses that bind DCs activate them to produce pro-inflammatory
cytokines and other antiviral molecules and/or get degraded to be
presented to specific T cells as peptides. Thanks to this, most viral
infections go clinically unnoticed and heal ‘‘spontaneously’’, being
dealt with efficiently by the host’s immune system. Certain viruses,
however, will successfully replicate in DCs. In this case, these cells
will act like other permissive cells with the added consequence that
they will migrate across the body, resulting in facilitated spread of
infection in addition or as an alternative to activating a defense
against it. A third possible outcome of virus–DC interaction is that
DCs will not digest and present all the viral particles they have
picked up, but will preserve some of them from inactivation so that
virions are transported to lymph nodes promoting target cell
infection. The overall result of at least certain viral infections can
thus be envisioned as a balance between the prevailing activity of
DCsintriggeringanimmuneresponseversustheabilityofvirusesto
exploit DCs or hamper their unique immune functions. This review
will mainlyfocusontheinsightsbrought into theeffectsviruses exert
upon the natural function of DCs during the last few years, while
referring to excellent recent reviews for other subjects.
DC Surface Molecules That Bind Virions
Most viruses exhibit a number of specific features that make
them highly immunogenic (Figure 1). DCs have evolved specific
surface molecules to uptake pathogens, in addition to expressing a
number of specific receptors for certain viruses (such as CD4 and
CXCR4 for HIV-1). DC-SIGN (CD209; dendritic cell specific
ICAM-3-grabbing non-integrin) and its close relative DC-SIGNR,
or L-SIGN found on liver endothelium [19], are some of the most
intensively studied pathogen receptors. It is a type II transmem-
brane C-type lectin specific for mannose and fucose residues that
promotes adhesion of DCs to endothelia and is therefore involved
in DC trafficking [20]. Although at first considered to be expressed
only on cDCs, DC-SIGN was later recognized to be expressed also
on B lymphocytes and macrophages, although it has not been
detected on the surface of Langerhans cells [19]. DC-SIGN is an
ICAM-3 receptor, essential in establishing the initial DC–T cell
contact for T cell activation [20]. It was soon understood that DC-
SIGN is also a target for pathogens ranging from mycobacteria to
Figure 1. Viral patterns that activate the immune system. A virion can be envisioned as a concentration of different patterns recognized by
the immune system: virtually all of its components can be used to start a response before the T cell compartment is active.
doi:10.1371/journal.ppat.1000384.g001
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binding of N-linked glycan substituents on viral spikes, thereby
enabling virus entry into cell lines expressing low levels of, if any,
specific receptors; it may function as a receptor alternative to the
specific one or as a non-essential adhesion factor concentrating
virions onto cells [21].
Binding of DC-SIGN by several pathogens has also been
reported to regulate inflammation and cytokine secretion by DCs
via NFkB [22]. In addition, it has recently been shown that DC-
SIGN can divert HIV-1 to the proteasome after associating to
leukocyte-specific protein 1 in cells infected in vitro, suggesting a
role for this molecule in crosspresentation to CD8
+ T cells [23],
while it also has a role in the formation of the infectious synapse (see
below). More and more viruses are being found to bind DCs via
DC-SIGN,includingherpesviruses,Ebolavirus,SARScoronavirus,
human hepatitis C virus (HCV), and dengue virus (DV) [24–29]. It
is still unclear whether DC-SIGN and related lectins are actual
pathogen-recognition receptors or, rather, antigen-binding recep-
tors whose functions have been subverted by pathogens.
Langerin (CD207) is a membrane marker expressed solely by
Langerhans cells, which do not express DC-SIGN [30]. In stark
contrast to DC-SIGN, langerin was shown to internalize HIV-1
virions into Birbeck granules and degrade them [31].
Another molecule, DEC-205 (CD205), a 205-kDa membrane
molecule that binds certain viruses, was discovered first in the
mouse, then in humans. It is a pan-DC-specific surface marker,
being expressed at high levels on DCs in the T cell areas of lymph
nodes in their steady state and even more when they are mature
[32]. In contrast with many endocytosis receptors that only recycle
to the cell surface from early endosomes, such as the mannose
receptor, targeting antigens to DEC-205 in murine spleen cells
allowed them to reach endolysosomes rich in MHC class II
products, enhancing the efficiency of antigen presentation to
CD4
+ T cells [32]. Because human DEC205 also proved to be a
useful target to prime MHC class I and class II, it is envisioned as a
promising candidate molecule for targeting antigens to DCs in
vivo with the purpose of priming naı ¨ve T cells [33]. However,
other surface molecules, like heparan sulfate and Fcc and mannose
receptors, also contribute to the uptake of viruses by DCs [34,35],
and novel virus-binding molecules are discovered continuously on
the surface of DCs, the last one being the C-type lectin surface
receptor DCIR [36]. The fate of virions encountering a DC is
partly determined by the receptors they bind. As shown for HIV,
binding specific receptors may determine entry and replication,
whereas binding DC-SIGN may lead mostly to transmission of
virus to T cells and/or degradation via proteasome resulting in
MHC class I presentation, while binding langerin may lead to
lysosomal degradation and MHC class II loading. Finally,
particular circumstances may affect viral binding and efficiency
of infection. For example, semen-derived enhancer of virus
infection (SEVI) fibers, which are abundant in human semen,
capture HIV virions and promote their attachment to target cells
[37]. These molecules may allow virions to bypass uptake by DC-
SIGN.
Pathogenetic Consequences of the Interaction
between DCs and Viruses
During viral infection, significant damage to the host can be a ‘‘side
product’’ of activating the immune system and of skewing the T
helper cell response towards Th1, Th2, Treg, and Th17. Because
DCs are pivotal in polarization of the Th response, they are definitely
key determinants of the pathogenetic outcome of viral infection and
also contribute in determining infectious disease severity.
Certain viruses promote their own persistence by favoring the
production of Th1-suppressive cytokines and altering cytokine
secretion. Although beneficial in recovery from helminth infesta-
tion, Th2 responses are known to have detrimental effects by
promoting inflammation, allergy, and fibrosis during viral
infection. Triggering of DC-SIGN has been proposed to have a
central role in both polarizing the Th response towards Th2 and
viral persistence [20,38]. New evidence shows that DC-SIGN
binding by HIV on human cDCs causes activation of Rho guanine
nucleotide-exchange factor LARG, which, in turn, is essential for
the formation of the infectious synapses and downregulation of IL-
12p70 secretion [39]. Thus, activation of DC-SIGN may favor the
production of a Th2-related cytokine profile during infection.
Another viral strategy to achieve a Th2 environment is to induce
DCs and other cell types to secrete Th2-inducing cytokines. The
best known example is probably respiratory syncytial virus (RSV):
although it does induce DC maturation, virulent RSV strains were
shown to inhibit IFN-a and IL-12p70 secretion by human DCs
[40]. In mice, RSV infection establishes a Th2 environment that
leads to airway infiltration [41] and at least some patients present
with signs of Th2-mediated lung injury [40]. In addition, while
vaccination attempts in the 1960s with inactivated RSV led to
exacerbation of disease, it is interesting that very recently
vaccination of mice against RSV was successfully obtained by
BCG, a potent Th1 inducer and recombinant for the N and M2
proteins of RSV, and that such protection was found to be
mediated mostly by a cellular immune response [42]. A Th2
environment seems so important to viruses that some of them go as
far as directly encoding proteins that interfere with immunoreg-
ulatory cytokines or proteins with immunomodulatory and/or
Th2 cytokine-like activity (i.e., human cytomegalovirus IL10 [43]).
DistinctstagesofDCgenerationmaybealteredbyviralinfection,
from hematopoietic progenitor differentiation, to maturation, or
even both (Figure 2) [38]. In mice, DC progenitors generated under
the influence of IL-10 are able to give rise to a DC subset that
induces antigen-specific expansion of functional CD4
+CD25
+ Treg
cells with strong suppressive functions [44]. The role of Treg cells is
normally to downregulate immune and inflammatory responses as
part of the healing process, but they may be activated to create an
immunosuppressive environment during certain viral infections.
Because maturation is essential for DC functionality, there are very
few viruses that do not interfere with it. Experiments performed on
human monocyte-derived cDCs show that different viruses downreg-
ulate distinct stages and events of the maturation process: HCV protein
was shown to downregulate expression of HLA-DR [45]; measles virus
and RSV rendered immune synapses between cDCs and T cells
unstable [46,47]; and HSV-1 downregulated expression of several
costimulatory molecules by cDCs [48], while influenza virus NS1
protein blocked their maturation [49]. On the other hand, other
viruses, such as vaccinia virus, may induce cDC maturation, but
interfere with antigen presentation nevertheless [50].
The outcome of viral disease is thought to be partly linked to the
numbers of and balance between pDCs and cDCs, on the basis of
observations made on patients. In patients infected with HSV, severity
of disease was found to be inversely correlated to the number of
circulating pDCs and to a blunted IFN-a release response during the
early phases of infection; clinical data show that patients with HSV-
associated acute retinal necrosis have lower numbers of peripheral
blood pDCs and exhibit impaired immune responses [51]. Similar
findings were obtained in patients infected with DV [52]. Along the
same line, during primary HIV-1 infection, pDCs have been found to
be reduced in numbers in peripheral blood and such a reduction was
associated to higher plasma viral loads [53]. The importance of pDCs
has also been demonstrated in the mouse model by preferentially
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pDC numbers correlated with protection [54]. A reduced number of
pDCs may either be genetically determined in given hosts, where viral
disease is expected to be consequently more severe due to poor IFN
type I response. In other instances, pDC numbers may be virally
determined, as suggested by findingsshowing that patientswith chronic
hepatitis C exhibited reduced numbers of pDCs as a possible result of
apoptosis induced by the interaction of HCV core protein with TLR-2
[55]. Alternatively, a decrease in numbers of pDCs may occur as a
consequence of their retention in lymphoid organs, possibly due to
higher viral replication in these sites, as suggested for HIV [56].
Interestingly, a recent study suggests that AIDS pathogenesis in
humans might stem from failure of adaptive immune responses to
control viral replication and from a consequent continuous stimulation
of pDCs and NK cells by the substantial amounts of circulating virus
[57]. Assuggested bythe authors,this mechanism might be generalized
for viruses reaching high titers in blood and targeting pDCs.
7DC involvement in viral pathogenicity is particularly evident in the
lung [54]. In this organ, inflammatory reactions have been well
recognized as part of the pathogenic scenario for many viral diseases. It
has long been noticed that asthmatic reactions may be linked to
pulmonary infection by viruses, especially paramyxoviruses, rhinovi-
ruses, and influenza. Increasing evidence seems to highlight the role of
DC-mediated polarization of the immune response in the development
of hyperreactivity. When a Th2 cytokine profile is created, IL-4, IL-10,
and IL -13 are predominant, and chronic disease is usually evident,
whilst recovery from pulmonary infection is generally associated with a
Th1 profile [58]. Again, pDCs have been detected at pulmonary sites
of viral infection [59]. A recent study describes describes a link between
these cells and allergic reactivity in a murine model; DCs were found to
upregulate their high-affinity IgE receptor during infection of the lung
by Sendai virus, as a result of IFN type I secretion by pDCs. The
expression of these receptors is essential to the development of mucous
cell metaplasia, one of the signs of airway hyperreactivity [60].
Quite a number of viruses find suitable intracellular conditions to
multiply in DCs. The ability to replicate in these cells certainly
represents an advantage for them, since DCs are located at the sites
of first encounter with the host and may represent the very first site
of primary replication. While replicating, viruses may influence DC
physiology: DV, for example, gives rise to a complex disease that is
strictly dependent on immunopathology. A typical feature of
dengue is that greater disease severity is noticed in individuals
who have undergone prior infection with a different DV serotype,
where antibody-dependent enhancement is believed to be respon-
sible for such a phenomenon, but recent evidence also links it to
increased production of DV and pro-inflammatory cytokines by
DV-infected mature DCs exposed to DV-immune sera. Such a
phenomenon was shown to be mediated by FccRIIa and
downregulated by DC-SIGN expression in human cDCs generated
in vitro, suggesting that entry of DV immune complexes via
FccRIIa, but not DC-SIGN, might activate cytokine production
[61]. DV is transmitted by direct inoculation of infected saliva from
mosquitoes into the host’s skin; therefore, skin DCs are probably
amongst the first permissive cells encountered expressing high levels
of DC-SIGN. In the light of evidence showing that DC precursors
capture DV mostly by DC-SIGN and are permissive to virus
replication [29,62], DV infection and replication probably initiates
via DC-SIGN, then compounds when antibodies are produced in a
Figure 2. Some effects of viral interaction with DCs. Certain viruses, like RSV, infect DCs, replicate in them, and cause them to mature, while
others, like several herpesviruses, dengue virus, and influenza virus, replicate and hinder maturation. Viruses like HPV do not replicate in DCs and are
only presented as antigens, while others, like HIV, are concentrated and delivered to their target organs by DCs, which thereby increase the chances
of virions to infect cells.
doi:10.1371/journal.ppat.1000384.g002
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complexes.
Herpesviruses are also capable of replication in DCs [63]. They
encode a number of early gene products that immediately affect DC
physiology to favor immune evasion. Several members of the
herpesvirus family attack the expression of costimulatory molecules
on the surface of DCs in vitro: HSV-1, for example, induces specific
CD83 degradation as early as 6 hours after infection of human cDCs
generated in vitro [64]. HSV-1 is known to replicate in DCs, resulting
mostly in downregulation of their activity as antigen-presenting cells
[63]. Immune dysfunction induced by HSV includes dowregulation of
the expression of several costimulatory molecules by mature DCs,
mostly mediated by viral proteins directly, together with inhibition of
the secretion of soluble Th1 mediators such as IL-12 [63,64]. Class II-
restricted presentation is also hampered by HSV-1 [64]. Similarly,
mouse cytomegalovirus alters the balance between stimulatory
molecules and inhibitory ones on the surface of infected murine DCs
[65]. These immunosuppressive mechanisms may prevail during
certain stages of host life and lead to reactivation of herpes infection.
However, one must bear in mind that only a percentage of DCs will be
infected, while a large fraction of DCs in vivo are expected to perform
efficient crosspresentation and priming, as shown for ex vivo DCs from
patients infected with cytomegalovirus [66]. HIV also has been
reported to preferentially infect a small fraction of blood cDCs [67].
Infected DCs are either prevented from maturing, or HIV-1 may select
for a subset of DCs that is resistant to maturation; in any case, HIV-
infected DCs exhibit very weak immunostimulatory activity.
Some Viruses Exploit DCs to Reach Their Target
Cells
Lentiviruses, and maybe other viruses as well, have developed
an exquisite way of exploiting DC trafficking and functions: they
get concentrated into and/or onto DCs at mucosal sites, where
they typically make contact with their hosts, then are shuttled to
lymph nodes where they get efficiently transferred to T cells of the
CD4
+ phenotype, infecting them. Again, most of our knowledge of
lentiviral transfer from DCs to T cells originates from studying
HIV-1 in in vitro-generated human cDCs. HIV sequestration by
DC-SIGN helps HIV evade immune responses and spread to
susceptible cells by a structure called the ‘‘infectious synapse’’
formed at the DC–T cell contact surface (Figure 3) [68].
Engagement of DC-SIGN on the surface of human cDCs by
HIV stimulates Rho-GTPase activity, which was found to be
essential for the formation of an actin structure giving origin to the
infectious synapse and for HIV replication [39]. Actual transfer of
HIV from cDCs to T cells has been reported to depend on gp120
and CD4 [69], but receptor clustering and actin tubule formation
have long been evident (Figure 3, [68]). Maturation of cDCs
seems to enhance virion transfer activity directed at target
cells[70].
DC-mediated viral transmission appears to be conserved across
lentiviruses infecting different species: simian immunodeficiency
virus (SIV) has been shown to be very efficiently transferred to
activated T cells by monocyte-derived immature DCs in vitro [71],
as has feline immunodeficiency virus (FIV) [72]. This suggests an
important mechanism in lentiviral pathogenesis. However, other
viruses have been shown to undergo DC-mediated transmission to
lymphocytes. Amongst the most recently studied ones, HTLV-1
can infect DCs, which, in turn, can rapidly transfer virus to
autologous primary CD4
+ T cells [73]. DC-mediated transfer of
HTLV-1 involves heparan sulfate proteoglycans and neuropilin-1,
resulting in productive infection and transformation of the
transfected T cells [74]. Even non-lymphotropic viruses such as
HCV may exploit this mechanism: HCV-pseudotyped virions
have been shown to be transinfected to cells of a hepatoma line
Figure 3. The infectious synapse model. At the site of mucosal entry, DCs concentrate HIV-1 via DC-SIGN. Virions are stored either in
‘‘virosomes’’, where their infectivity is even preserved, or (and?) on the DC surface and, once in the lymph node, DCs deliver them actively to target
CD4
+ T cells. Several molecules are involved in this event that closely resembles the transmission of acetylcholine along the nerve (synapse), in that
virions are actively transported in vesicles along actin fibers and released outside the cells where they immediately find their receptors, which have
been concentrated on the T cell side. This mechanism may be active also for other viruses, like HCV and SARS coronavirus.
doi:10.1371/journal.ppat.1000384.g003
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Recent studies show that DC-SIGN and CD150 are both involved
in direct DC infection by and subsequent transmission of measles
virus, indicating a prominent role for DCs during the initiation
and dissemination of yet another virus infection [76].
Can We Exploit DCs to Improve Immune
Responses during Vaccination?
Unravelling the details of DC biology brought about hopes for
their possible use as immuno-adjuvants and modulators to
enhance immune responses against viral infections [77]. Clinical
trials evaluating vaccination of patients and experimental animals
with ex vivo-generated cDCs pulsed with tumor antigens have
provided proof-of-principle that therapeutic effects may be
obtained this way. However, this gave rise to surprisingly few
studies addressing the concurrent issue as to whether DCs can be
used to boost protective immunity to viruses and to skew the
immune response towards the direction of healing. Because the
generation and maturation process that DCs follow determines
their potential of polarizing the T cell response and its direction,
different strategies and methods for producing clinically useful
DCs should be experimented.
The use of DCs in the therapy of HIV and SIV infection has
been explored; in 2004, results were published obtained from
untreated HIV-infected patients vaccinated with autologous
monocyte-derived DCs loaded with autologous inactivated HIV
[78]. A year following vaccination, all patients exhibited plasma
viral load decreases that were significantly correlated with their
percentages of HIV-specific CD4
+ and CD8
+ T cells. To our
knowledge, this was the only trial that reported successful use of
DCs in the therapy of a human viral disease. More recently, a
clinical trial on 18 patients with HIV was carried out by injecting
them with monocyte-derived DCs loaded with peptides from Gag,
Pol, and Env proteins. Significant increases in T cell immunity
were reported, but viremia was not measured [79]. Similarly,
human papillomavirus (HPV) 16/18 full-length E7 antigen-pulsed
mature autologous cDC vaccination was shown to generate or
boost anti-E7 immune responses in patients with cervical cancer,
but the overall beneficial clinical effects have not yet been reported
[80]. The protocol to generate the DCs for these studies included
growth of adherent autologous peripheral blood monocytes in
vitro in the presence of granulocyte macrophage colony
stimulating factor (GMCSF) and IL-4, and maturation induction
after antigen loading with a cocktail of TNFa, IL-1b, and other
cytokines, as recommended for clinical-grade DC production.
Because the cat infected by FIV is accepted as a good non-
primate model for the study of AIDS, we investigated the
vaccination of naı ¨ve cats with autologous cDCs generated in vitro
and loaded with whole inactivated FIV. In our case, maturation
could be achieved by the use of LPS, since feline cytokines were
unavailable at the time of the study and this was the only agent
able to induce the ability to prime alloreactivity of cat allogeneic T
cells [81]. Our results were encouraging, in that all cats exhibited
antibody and cellular immunity against FIV antigens, but no
protection against challenge with infectious FIV was achieved
[82]. In the hypothesis that eliciting memory responses from
infected cats might be less demanding than inducing primary
responses, we successively tested the same vaccination protocol on
FIV-infected cats. In this case, we also assessed viremia levels
before and after vaccination, a sustained reduction of viral load
being the main goal of the latter approach. Again, we detected
increased cellular responses to FIV but no effect on viral load was
to be seen [83]. One hypothesis to explain the failure of our DC
vaccination protocols to alter the course of FIV infection might be
that DCs were not the ‘‘suitable’’ type, in terms of molecules
expressed. In this case, it might be interesting to test different
protocols for DC generation and maturation to explore the effect
of different cytokines and maturation stimuli on the generation of
‘‘protective’’ DCs. This hypothesis is also suggested by recent data
obtained in the mouse model that suggests DCs generated in vitro
with GMCSF and IL-4 might not be the most appropriate ones to
achieve protective immunity activation [11].
Protocols to generate DCs in vitro are often considered too
cumbersome to achieve sufficiently high cell numbers and in the
appropriate maturation status. Several groups, therefore, aimed at
targeting antigens to DCs in vivo with encouraging results [77].
Many reports show that targeting DCs via different receptors
(langerin, FccR, DEC205, and others) improves the ability of
different antigens to induce both CD4
+ and CD8
+ T cells [84,85].
Continued studies are needed to assess whether the skewing of the
immune response can be carried out by targeting antigens and
other surface DC molecules at the same time, and it remains to be
seen whether in vitro-derived DCs are efficient not only at
inducing immunity but also at directing the immune response to
specific types.
Conclusions
The ‘‘iceberg effect’’, whereby most viral infections recover with
very few, if any, symptoms while a minority of infections lead to
serious illness and death, suggests that the most frequent outcome
of infection is immune activation, indirectly proving that this is the
prevailing role for DCs. However, viruses may also exploit DCs at
several steps of their life cycle, limiting immune responses rather
than actually suppressing them. Additionally, it is a well-known
advantage for viruses to preserve their hosts rather than
impoverishing their possible replication reservoir. Thus, a
successful virus may be viewed as one that permits immune
reactions to take place once a new generation of virions has been
released into the host environment. A key event in this respect is
the relationship established between viruses and DCs; some viruses
can replicate in DCs or merely alter/hijack their functions to their
benefit. Shedding light on this relationship might provide means to
develop alternatives to classical vaccination strategies in the design
of immunotherapeutic approaches to chronic viral infections with
global impact such as HCV and HIV. More insight into the field
should be gained by in vivo studies aimed at confirming the great
deal of results obtained in vitro in the last decade.
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